LAWRENCE TAWIAH: Open Payments
NPI 1508223108 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$958 in 56 payments from 16 companies in 2025. Trend: 2023 $492 · 2024 $649 · 2025 $958
Food & beverage: $958
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 18 | $237 |
| Lilly USA, LLC | 8 | $172 |
| Novo Nordisk Inc | 8 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| PFIZER INC. | 3 | $62 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Boston Scientific Corporation | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
Products named: MOUNJARO, Wegovy, OTEZLA, REPATHA, EVENITY, TRINTELLIX, ELIQUIS, JARDIANCE.
Industry payments across MD — which companies pay providers there.
